(PharmaNewsWire.Com, August 17, 2017 ) Insulin maintains sugar levels in the blood and essential for the people suffering from type I diabetes & type II diabetes. The development of insulin delivery devices has been encouraged from the past years. These devices are used to deliver the insulin doses via parenteral route rather than oral route of administration. Insulin delivery devices promote absorption rate of insulin into blood stream from the site of injection to execute immediate pharmacological action of insulin. Some of the majorly used insulin delivery devices such as insulin syringes, insulin pens, insulin pen needles, insulin pumps, and insulin jet injectors.
Growing rate of diabetes patients, rising exposure of population towards the diabetes risk factors, changes in lifestyle habits, and increasing demand for human insulin are driving the growth of global insulin delivery devices Industry. In addition, availability of favorable medical reimbursements, increasing healthcare expenditure, rising advancements in human insulin delivery devices technologies, growing focus of Industry players on the development & commercialization of advanced human insulin delivery devices (such as pens & portable insulin pumps) are further fueling the growth of global insulin delivery devices Industry. However, stringent regulatory policies for product approval and requirement of high costs for the product manufacturing are restraining the growth of global insulin delivery devices Industry.
Global insulin delivery devices Industry is segmented based on the type and application. Based on type, the Industry is further sub-segmented as insulin syringes, insulin pens, insulin pen needles, insulin pumps, and insulin jet injectors. Of these, insulin syringes commanded the largest share of the global insulin delivery devices Industry in 2015, whereas insulin pens segment is estimated to grow at the highest CAGR during the forecast period 2015-2020. Based on application, the Industry is segmented as type I diabetes and type II diabetes.
On the basis of geographical region the global insulin delivery devices Industry is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America accounted for the largest share of 40.5% of the global insulin delivery devices Industry in 2015, whereas Asia-Pacific is estimated to grow at the highest CAGR of 9.10% during the forecast period 2015-2020.
The key players in global insulin delivery devices Industry such as, Becton, Dickinson and Company (U.S.), Sanofi (France), Novo Nordisk A/S (Denmark), Julphar (U.A.E.), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Ypsomed AG (Switzerland), Wockhardt Ltd. (India), B. Braun Meselgen AG (Switzerland), and Biodel Inc. (U.S.).
Key Points from Table of Contents Overview Executive Summary Key Inferences New Developments Drivers, Restraints, Opportunities, and Challenges Analysis (DROC) Global Insulin Delivery Devices Industry: Segmentation Type o Insulin Syringes o Insulin Pens o Insulin Pen Needles o Insulin Pumps o Insulin Jet Injectors Application o Type I Diabetes o Type II Diabetes Geographical Analysis North America Europe Asia-Pacific Latin America Middle East & Africa Strategic Analysis PESTLE analysis Porters Five analysis Industry Leaders' Analysis Competitive Landscape
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
